



## **ESC Declaration of Interest Report**

### **2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy**

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved in July 2020.

The current policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI)

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Auricchio Angelo | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Sorin Group : cardiac rhythm management<br>- Boston Scientific : Device-based therapy of heart failure |
|                  | <b>2020</b><br>Financial Declaration<br>- Boston Scientific : cardiac rhythm management<br>- Medtronic : cardiac rhythm management<br>- Cardiac Dimensions : cardiac rhythm management<br>- CorVia : cardiac rhythm management<br>- Microport (CRM) : cardiac rhythm management                           |
| Barbash Israel   | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Sanofi Aventis : Hyperlipidemia<br>- Abbott : TAVI   |
|                  | <b>2020</b><br>Nothing to be declared   |
| Barrabes Jose A  | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Astrazeneca : Acute coronary syndromes, payment for educational activities                             |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Barrabes Jose A      | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- I have received honoraria from the Spanish Society of Cardiology (SSC) as one of the directors of the Mastership Program in Acute Cardiac Care promoted by the SSC. This program has received financial support by Sanofi (with interest in lipid lowering agents and antiplatelet agents).</li> </ul>  |
| Boriani Giuseppe     | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Pacemaker, cardioverter defibrillators</li> <li>- Medtronic : Pacemaker, cardioverter defibrillators</li> <li>- Biotronik : Pacemaker, cardioverter defibrillators</li> </ul> <p><b>2020</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Boston Scientific : Pacemaker, cardioverter defibrillators</li> <li>- Medtronic : Pacemaker, cardioverter defibrillators</li> </ul> |
| Braunschweig Frieder | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart Failure</li> <li>- Orion : Heart Failure</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Braunschweig Frieder | <b>2019</b> <ul style="list-style-type: none"> <li>- Abbott : Pacemaker</li> <li>- Medtronic : Pacemaker</li> <li>- Biotronik : Pacemaker</li> </ul>   |
|                      | <b>2020</b> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Novartis : Heart Failure</li> <li>- Orion : Heart Failure</li> <li>- Abbott : Pacemaker</li> <li>- Medtronic : Pacemaker</li> <li>- Biotronik : Pacemaker</li> </ul>   |
| Brignole Michele     | <b>2019</b> <p>Nothing to be declared</p>  |
|                      | <b>2020</b> <p>Nothing to be declared</p>  |
| Burri Haran          | <b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Bayer : Cardiology</li> <li>- Medtronic : CIED</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert      | Type of Relationship with Industry  |
|-------------|---|
| Burri Haran | <p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Member of the Swiss Working Group of Pacing and Electrophysiology</li> </ul>  |
|             | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CIED consultancy</li> <li>- Abbott : CIED education</li> <li>- Medtronic : CIED education</li> <li>- Biotronik : CIED education</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert       | Type of Relationship with Industry   |
|--------------|--|
| Coats Andrew | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Faraday Australia : Acute MI<br>- CVRx : Autonomic devices<br>- ESN Cleer : Biomarkers<br>- Actimed : Cancer<br>- Bayer AG (event review committee member) : CV disease<br>- CorVia : Device for HFpEF<br>- Cardiac Dimensions : Devices for MR<br>- Novartis : Heart Failure<br>- Servier : Heart Failure<br>- Menarini : Heart Failure<br>- Astra Zeneca : Hyperkalaemia<br>- Vifor International : Iron deficiency<br>- Arena : New drug development in acute heart failure<br>- Nutricia : Nutrition<br>- WL Gore : Prosthetic Valves<br>- Respicardia : Sleep Apnoea |
|              | <b>2020</b><br>Financial Declaration<br>- Faraday Australia : Acute MI<br>- CVRx : Autonomic devices<br>- ESN Cleer : Biomarkers   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry   |
|--------------------|--|
| Coats Andrew       | <p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Actimed : Cancer</li> <li>- Bayer AG (event review committee member) : CV disease</li> <li>- CorVia : Device for HFpEF</li> <li>- Cardiac Dimensions : Devices for MR</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- Menarini : Heart Failure</li> <li>- Astra Zeneca : Hyperkalaemia</li> <li>- Vifor International : Iron deficiency</li> <li>- Arena : New drug development in acute heart failure</li> <li>- Nutricia : Nutrition</li> <li>- WL Gore : Prosthetic Valves</li> <li>- Respicardia : Sleep Apnoea</li> </ul> |
| Deharo Jean-Claude | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Medtronic : CRM</li> <li>- Microport : CRM</li> <li>- Bayer : Drugs</li> <li>- Boehringer-Ingelheim : Drugs</li> <li>- Novartis : Drugs</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Deharo Jean-Claude | <b>2019</b> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Drugs</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Biotronik : CRM</li> <li>- Microport : CRM</li> </ul>   |
|                    | <b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Medtronic : CRM</li> <li>- Microport : CRM</li> <li>- Bayer : Drugs</li> <li>- Boehringer-Ingelheim : Drugs</li> <li>- Novartis : Drugs</li> <li>- Bristol Myers Squibb : Drugs</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Biotronik : CRM</li> <li>- Microport : CRM</li> </ul> |



## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Delgado Victoria | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- GE Healthcare : 3-dimensional imaging workshop (2000 euro)</li> <li>- Medtronic : aortic stenosis (payment speaker fee 900 euro)</li> <li>- Bayer : diabetes - steering committee (750 euro)</li> <li>- Abbott Vascular : Mitraclip (payment speaker fee 1200 euro)</li> <li>- Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro)</li> </ul><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br><ul style="list-style-type: none"> <li>- Edwards Lifesciences : Aortic valve stenosis</li> <li>- Bayer : Heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abbott Vascular : Mitraclip</li> <li>- Edwards Lifesciences : Tricuspid valve</li> </ul> |
|                  | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- Medtronic : aortic stenosis (speaker fee in 2019 &lt;1000 euro)</li> <li>- MSD : diabetes - speaker fee (800 euro)</li> <li>- GE Healthcare : echocardiography (&lt;2000 euro)</li> <li>- Novartis : heart failure (speaker fee 800 euro)</li> <li>- Abbott Vascular : Mitral valve disease (&lt;2000 euro)</li> <li>- Edwards Lifesciences : valvular heart disease (&lt;2000 euro)</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Delgado Victoria    | <p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- GE Healthcare : echocardiography</li> <li>- Edwards Lifesciences : tricuspid valve disease</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Member of AHA, associate editor of Circulation and JASE</li> </ul> |
| Diller Gerhard Paul | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation</li> <li>- Actelion : Pulmonary hypertension</li> </ul> <p><b>2020</b></p> <p>Nothing to be declared</p>   |
| Glikson Michael     | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Sorin Group : CHF</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Medtronic : CIEDS</li> <li>- Biotronik : CIEDS</li> <li>- Pfizer : NOACS</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry   |
|------------------|--|
| Glikson Michael  | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : LAA</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Medtronic : CIEDS</li> <li>- Biotronik : CIEDS</li> <li>- Pfizer : NOACS</li> </ul>   |
| Israel Carsten W | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Chemie AG : Antiarrhythmic drugs</li> <li>- BMS-Pfizer : Apixaban</li> <li>- Astra Zeneca : Brilique</li> <li>- Boehringer-Ingelheim : Dabigatran</li> <li>- Sanofi Aventis : Dronedarone</li> <li>- Daiichi Sankyo : Edoxaban</li> <li>- Servier : Ivabradin</li> <li>- Zoll Medical : Life Vest</li> <li>- Boston Scientific : Pacemakers, ICDs</li> <li>- Biotronik : Pacemakers, ICDs</li> <li>- Abbott : Pacemakers, ICDs, CRT</li> <li>- Microport : Pacemakers, ICDs, CRT</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Israel Carsten W | <p><b>2019</b></p> <ul style="list-style-type: none"> <li>- Medtronic : Pacemakers, ICDs, CRT, ILR</li> <li>- Bayer Healthcare : Rivaroxaban</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilique</li> <li>- Zoll Medical : Life Vest</li> <li>- Medtronic : Pacemakers, ICDs, CRT, ILR</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antiarrhythmics</li> <li>- Berlin Chemie AG : Antiarrhythmics</li> <li>- Boehringer-Ingelheim : oral anticoagulation</li> <li>- Daiichi Sankyo : oral anticoagulation</li> <li>- Pfizer : oral anticoagulation</li> <li>- Bayer Healthcare : oral anticoagulation</li> <li>- Bristol Myers Squibb : oral anticoagulation</li> <li>- Abbott : Pacemaker, ICD, CRT</li> <li>- Boston Scientific : Pacemaker, ICD, CRT</li> <li>- Medtronic : Pacemaker, ICD, CRT</li> <li>- Biotronik : Pacemaker, ICD, CRT</li> <li>- Microport : Pacemaker, ICD, CRT</li> <li>- Zoll Medical : sudden cardiac death</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry   |
|------------------|--|
| Israel Carsten W | <b>2019</b><br>Other Positions of Influence<br><br>Membership or affiliation in political or advocacy groups working in the field of cardiology.<br>- German Cardiac Society Heart Rhythm Society World Society of Arrhythmias<br><br>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.<br>- Member of the Board of the World Society of Arrhythmias   |
|                  | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Berlin Chemie AG : Antiarrhythmic drugs<br>- BMS-Pfizer : Apixaban<br>- Astra Zeneca : Brilique<br>- Impulse Dynamics : Cardiac Contractility Management<br>- Boehringer-Ingelheim : Dabigatran<br>- Sanofi Aventis : Dronedarone<br>- Daiichi Sankyo : Edoxaban<br>- Servier : Ivabradin<br>- Zoll Medical : Life Vest<br>- Boston Scientific : Pacemakers, ICDs<br>- Biotronik : Pacemakers, ICDs, CRT<br>- Microport : Pacemakers, ICDs, CRT<br>- Medtronic : Pacemakers, ICDs, CRT, ILR<br>- Abbott : Pacemakers, ICDs, CRT, Occluder |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Israel Carsten W | <p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Rivaroxaban</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilique</li> <li>- Zoll Medical : Life Vest</li> <li>- Medtronic : Pacemakers, ICDs, CRT, ILR</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antiarrhythmics</li> <li>- Berlin Chemie AG : Antiarrhythmics</li> <li>- Boehringer-Ingelheim : oral anticoagulation</li> <li>- Daiichi Sankyo : oral anticoagulation</li> <li>- Pfizer : oral anticoagulation</li> <li>- Bayer Healthcare : oral anticoagulation</li> <li>- Bristol Myers Squibb : oral anticoagulation</li> <li>- Abbott : Pacemaker, ICD, CRT</li> <li>- Boston Scientific : Pacemaker, ICD, CRT</li> <li>- Medtronic : Pacemaker, ICD, CRT</li> <li>- Biotronik : Pacemaker, ICD, CRT</li> <li>- Microport : Pacemaker, ICD, CRT</li> <li>- Zoll Medical : sudden cardiac death</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : LAA occluders</li> <li>- Microport : Pacemaker, ICD, CRT</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Israel Carsten W | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Deutsche Herzstiftung</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Member of the Board of the World Society of Arrhythmias Editor of "Herzschrittmachertherapie und Elektrophysiologie"</li> </ul>  |
| Keren Andre      | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Vifor International : Iron deficiency</li> <li>- CTS Pharmaceuticals ISrael : Iron deficiency</li> </ul> <hr/> <p><b>2020</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure</li> <li>- Vifor International : Iron deficiency</li> <li>- CTS pharmaceuticals : iron Deficiency</li> </ul> |
| Knops Re         | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert   | Type of Relationship with Industry  |
|----------|---|
| Knops Re | <p><b>2019</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Supplier - I am consultant for a start-up company Atacor (pacemaker company). For my activities I will be compensated with a modest amount of stock options in 2020 Value &lt; 10.000 Euro</li> </ul> |
|          | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Medtronic : CIED</li> </ul>   |



## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert        | Type of Relationship with Industry  |
|---------------|---|
| Knops Re      | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Supplier - I am consultant for a start-up company Atacor (pacemaker company). For my activities I will be compensated with a modest amount of stock options in 2020 Value &lt; 10.000 Euro</li> </ul>  |
| Kotecha Dipak | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- MyoKardia : Clinical trials in heart failure and atrial fibrillation (Advisory Board)</li> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Product development in heart failure and atrial fibrillation (Advisory Board)</li> <li>- Atricure : Symposium on atrial fibrillation (Speaker fees)</li> </ul> <hr/> <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Kotecha Dipak       | <p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul> |
| Kronborg Mads Brix  | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Orion : Atrial fibrillation</li> </ul> <p><b>2020</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer : speakers fee</li> </ul>   |
| Leclercq Christophe | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : devices</li> <li>- Boston Scientific : devices</li> <li>- Medtronic : devices</li> <li>- Biotronik : devices</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Leclercq Christophe | <b>2019</b> <ul style="list-style-type: none"> <li>- Microport : devices</li> <li>- Zoll Medical : WCD</li> </ul>   |
|                     | <b>2020</b> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Biotronik : device</li> <li>- Abbott : devices</li> <li>- Boston Scientific : devices</li> <li>- Medtronic : devices</li> <li>- Microport : devices</li> </ul>  |
| Merkely Bela        | <b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT course</li> <li>- Abbott : CRT/ICD</li> <li>- Astra Zeneca : HF</li> <li>- Biotronik : ICD/CRT</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiac rhythm management</li> <li>- Boston Scientific : CRT</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Merkely Bela         | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Abbott : CRT/ICD<br>- Boehringer Ingelheim : ICD / CRT<br>- Biotronik : ICD/CRT<br><br>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Medtronic : cardiac rhythm management<br>- Boston Scientific : CRT |
|                      | <b>2019</b><br>Nothing to be declared  |
| Michowitz Yoav       | <b>2020</b><br>Nothing to be declared  |
|                      | <b>2019</b><br>Other Positions of Influence<br><br>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.<br>- I received institutional research grants from the Novo Nordisk Foundation  |
| Nielsen Jens Cosedis | <b>2020</b><br>Other Positions of Influence<br><br>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.<br>- Member of Danish Heart Foundation   |
|                      | <b>2019</b><br>Other Positions of Influence<br><br>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.<br>- I received institutional research grants from the Novo Nordisk Foundation  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Nielsen Jens Cosedis    | <p><b>2020</b></p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- I received institutional research grants from the Novo Nordisk Foundation</li> </ul>  |
| Starck Christoph Thomas | <p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Angiodynamics : Angiovac</li> <li>- Biotronik : CIED</li> <li>- Cook Medical : Lead Extraction</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Cook Medical : Lead Extraction</li> </ul> <hr/> <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Angiodynamics : Angiovac</li> <li>- Biotronik : CIED</li> <li>- Cook Medical : Lead Extraction</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Hylomorph AG : Biomedical Engineering</li> <li>- Cook Medical : Lead Extraction</li> </ul> |
| Thylen Ingela           | <p><b>2019</b></p> <p>Nothing to be declared</p>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Thylen Ingela       | <b>2020</b><br><br>Nothing to be declared   |
| Tolosana Jose Maria | <b>2019</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Abbott : consultancy<br>- Medtronic : pacemaker/consultancy<br>- Boston Scientific : Pacemaker/ICD<br><hr/> <b>2020</b><br>Financial Declaration<br>- Abbott : consultancy<br>- Medtronic : pacemaker/consultancy<br>- Boston Scientific : Pacemaker/ICD |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                 | Type of Relationship with Industry  |
|------------------------|---|
| Abdelhamid Magdy       | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>  |
| Abdrakhmanov Ayan      | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> <li>- Astana Medical University, professor of Internal Medicine - part time</li> </ul>  |
| Abi Saleh Bernard      | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Aboyans Victor         | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Bristol Myers Squibb : Antithrombotic therapies</li> <li>- Astrazeneca : Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Peripheral Artery Disease</li> </ul> |
| Al Saadi Ahmad Rasheed | <p><b>2020</b></p> <p>Nothing to be declared</p>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Antonio Natalia     | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br/>- Abbott : Cardiac resynchronization Therapy</p>   |
| Arbelo Elena        | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Biosense Webster : Atrial fibrillation</p>   |
| Asteggiano Riccardo | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.<br/>- Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</p>   |
| Atar Ilyas          | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Abbott : Speaker fees</p>  |
| Bajric Mugdim       | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- University Tuzla : Internal medicine<br/>- University clinical center Tuzla : Invasive cardiology-regular job duties- employee</p> |



## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Bajric Mugdim           | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> <li>- Chief of Clinic for invasive cardiology , which includes management duties and interventional cardiologists (MD) duties. Average annual income of 25000 euros. My position is not in competition with ESC.</li> </ul>  |
| Baron Esquivias Gonzalo | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Daiichi Sankyo : Anticoagulation</li> <li>- Sanofi Aventis : dislipemia</li> <li>- Recordati International : Dislipemia</li> <li>- Novartis : heart failure</li> <li>- Rovi : heart failure</li> <li>- Biotronik : pacing</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Daiichi Sankyo : anticoagulation</li> <li>- Novartis : Heart Failure</li> <li>- Rovi : Heart Failure</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                  | Type of Relationship with Industry  |
|-------------------------|---|
| Baron Esquivias Gonzalo | <b>2020</b><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br>- Novartis : heart failure  |
| Bauersachs Johann       | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Pfizer : Afib, Amyloidosis<br>- Daiichi Sankyo : Afib, CAD<br>- Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure<br>- Bayer : Afib, heart failure<br>- Bristol Myers Squibb : Afib, heart failure<br>- Amgen : CAD, Heart Failure<br>- Novartis : Heart Failure<br>- Servier : Heart Failure<br>- CVRx : Heart Failure<br>- Cardior : Heart Failure<br>- Vifor International : heart failure, hyperkalemia<br>- Astrazeneca : heart failure, hyperkalemia<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br>- Zoll Medical : Arrhythmia<br>- Abiomed : cardiogenic shock<br>- Vifor International : Heart failure<br>- CVRx : Heart Failure |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                     | Type of Relationship with Industry   |
|----------------------------|--|
| Biffi Mauro                | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CRT, pacing, defibrillation, CIED therapy, heart failure</li> <li>- Biotronik : CRT, pacing, electrophysiology, heart failure, heart failure</li> <li>- Boston Scientific : defibrillation, CIED therapy, heart failure</li> <li>- Zoll Medical : defibrillation, heart failure</li> </ul> |
| Bini Roberto               | <p><b>2020</b></p> <p>Nothing to be declared</p>   |
| Birgersdotter-Green Ulrika | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Medtronic : CRM</li> <li>- Biotronik : CRM</li> </ul>   |
| Bongiorni Maria Grazia     | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Micra Leadless</li> <li>- Boston Scientific : SCD and Rhythmia</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry   |
|------------------|--|
| Borger Michael A | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul> |
| Borgquist Rasmus | <p><b>2020</b></p> <p>Nothing to be declared</p>   |
| Bouhouch Rachida | <p><b>2020</b></p> <p>Nothing to be declared</p>   |
| Bytyci Ibadete   | <p><b>2020</b></p> <p>Nothing to be declared</p>   |
| Cano Perez Oscar | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : development of an educational platform</li> <li>- Abbott : High density mapping</li> <li>- Biosense Webster : intracardiac echocardiography</li> <li>- Medtronic : Physiological pacing</li> </ul>                       |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry   |
|--------------------|--|
| Celutkiene Jelena  | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Amgen : heart failure</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : heart failure</li> </ul> |
| Chasnoits Alexandr | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : antithrombotic therapy</li> </ul>   |
| Chow Anthony       | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED and mapping studies</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Cikes Maja          | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation, amyloidosis</li> <li>- Astra Zeneca : coronary heart disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Orion : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure</li> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul> |
| Daubert Jean-Claude | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Member of Haute Autorité de Santé (Commission de Transparence), Saint-Denis, France</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Drossart Inga      | <b>2020</b><br><br>Nothing to be declared   |
| Ellenbogen Kenneth | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Biotronik : Lectures<br>- Abbott : Lectures, Honoraria, Medical Advisory Board<br>- Boston Scientific : Medical Advisory Board, DSMB, Lectures<br>- Medtronic : Medical Advisory Board, DSMB Lectures<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br>- Boston Scientific : Pacing therapy<br>- Medtronic : Pacing therapy |
| Elliott Perry Mark | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Astra Zeneca : Amyloidosis<br>- Genzyme Sanofi : Enzyme replacement therapy Fabry disease<br>- MyoKardia : Hypertrophic Cardiomyopathy<br>- PeerVoice : Hypertrophic Cardiomyopathy<br>- Idorsia : Treatment for Fabry Disease<br>- Pfizer : Treatment for TTR amyloidosis   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry   |
|-----------------------|--|
| Elliott Perry Mark    | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.<br/>- Cardiomyopathy UK; International Cardiomyopathy Network (ICON)</p>  |
| Etsadashvili Kakhaber | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Bayer : DOACs<br/>- Servier : Hypertension</p>  |
| Fabritz Larissa       | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Roche Diagnostics : cardiovascular</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br/>- British Heart Foundation : cardiovascular<br/>- European Union Horizon 2020 : cardiovascular</p> |
| Falk Volkmar          | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Berlin Heart : Advisory<br/>- Novartis : Consultancy<br/>- Abbott : Educational Grant for HCP's</p>  |



## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                     | Type of Relationship with Industry  |
|----------------------------|---|
| Falk Volkmar               | <b>2020</b> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> </ul>   |
| Fauchier Laurent           | <b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- XO : Healthcare</li> </ul>          |
| Fernandez-Aviles Francisco | <b>2020</b> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Healthcare - VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE - EDWARDS LIFESCIENCES</li> </ul> |
| Foldager Dan               | <b>2020</b> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Private member of the danish heart association ("Hjerteforeningen") for whom I work as a volunteer (mentoring patients, patient supporter at Herlev Hospital, speaker a.o.)</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                            | Type of Relationship with Industry  |
|-----------------------------------|---|
| Fragakis Nikolaos                 | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Pfizer : speaker fees</li> <li>- Menarini : speaker fees</li> </ul>           |
| Gadler Fredrik                    | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Gallego Garcia De Vinuesa Pastora | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Geller Laszlo Alajos              | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Speaker fee</li> <li>- Biotronik : Speaker fee</li> <li>- Johnson &amp; Johnson : Speaker fee</li> <li>- Abbott Vascular : Speaker fee</li> </ul> |
| Gorenek Bulent                    | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Gorenek Bulent      | <b>2020</b> <ul style="list-style-type: none"> <li>- Sanofi Aventis : ACS</li> <li>- Roche Diagnostics : ACS</li> <li>- Bayer : Atrial Fibrillation</li> <li>- Sandoz : Atrial fibrillation</li> <li>- Sanovel : Atrial fibrillation</li> <li>- Daiichi Sankyo : Atrial Fibrillation, ACS</li> <li>- Deva : Hypertension</li> </ul>  |
| Groben Laurent      | <b>2020</b><br><br>Nothing to be declared  |
| Guerra Ramos Jose M | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> <li>- Abbott : Consultancy</li> <li>- Zoll Medical : Consultancy</li> </ul><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). <ul style="list-style-type: none"> <li>- Biosense Webster : Research funding to my research group</li> </ul> |
| Haggui Abdeddayem   | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> <li>- Medtronic : Honoraria, investigator</li> <li>- Boston Scientific : Honoraria, investigator, advisory board fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Servier : speaker fees</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                  | Type of Relationship with Industry  |
|-------------------------|---|
| Haggui Abdeddayem       | <b>2020</b><br>- Philadelphia Pharma : speaker fees   |
| Haugaa Kristina Hermann | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Novartis : speaker fees  |
| Hendriks Jeroen         | <b>2020</b><br><br>Nothing to be declared   |
| Kahan Thomas            | <b>2020</b><br>Financial Declaration<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br>- Medtronic : Renal denervation<br>- Recor : Renal denervation   |
| Kalejs Oskars           | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Astra Zeneca : Cardiovascula Pharmacotherapy<br>- Servier : Cardiovascular Pharmacotherapy<br>- Novartis : Cardiovascular Pharmacotherapy.<br>- Bayer AG : Cardiovascular Pharmacotherapy. |
| Kalysov Kurbanbek       | <b>2020</b><br><br>Nothing to be declared   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Karvonen Jarkko   | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CRT</li> <li>- Medtronic : Leadless pacing</li> </ul>  |
| Katus Hugo        | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer Ingelheim : Symposium General Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Chair symposium anticoagulation therapies</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Healthcare - HEART FAILURE - Co-founder of a start up on gene therapy (AaviGen) for heart failure. No earnings</li> </ul> |
| Khachatryan Armen | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Kichou Brahim     | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Hypertension</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry   |
|-----------------------|--|
| Konradi Aleksandra    | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertension</li> </ul>  |
| Koskinas Konstantinos | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul> |
| Laish-Farkash Avishag | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : consultancy</li> <li>- Biotronik : proctoring CRT implantation</li> <li>- Boehringer-Ingelheim : speaker fee</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry   |
|-----------------------|--|
| Laish-Farkash Avishag | <b>2020</b><br>Travel and meeting support from healthcare industry, independent of the above activities.<br>- Biotronik : EMB (Expert Meeting Berlin) annual meeting   |
| Law Hannah            | <b>2020</b><br>Nothing to be declared  |
| Lewis Basil S         | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Vifor International : Heart failure<br>- Kowa : Lipidology<br>- CSL Behring : Lipidology, Secondary prevention<br><br>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Kowa : Lipidology |
| Leyva Francisco       | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Abbott : Device therapy<br>- Medtronic : Device therapy<br>- Microport : Device therapy   |
| Linde Cecilia         | <b>2020</b><br>Financial Declaration<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br>- Roche Diagnostics : heart failure biomarkers  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert               | Type of Relationship with Industry  |
|----------------------|---|
| Linde Cecilia        | <b>2020</b> <ul style="list-style-type: none"> <li>- Astra Zeneca : heart failure biomarkers, proteomics lipidomics</li> </ul> <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Stockholm County Council : devices and heart failure</li> <li>- Swedish heart lung foundation, : devices and heart failure</li> <li>- Swedish research council : heart failure epidemiology</li> </ul>   |
| Linker Nicholas John | <b>2020</b> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Trustee and Medical Director of the Arrhythmia Alliance</li> </ul>   |
| Lochen Maja-Lisa     | <b>2020</b> <p>Nothing to be declared</p>   |
| Lumens Joost         | <b>2020</b> <p>Nothing to be declared</p>   |
| Mairesse Georges H   | <b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : antico</li> <li>- Pfizer : antico</li> <li>- Bristol Myers Squibb : antico</li> <li>- Daiichi Sankyo : cholesterol</li> <li>- Abbott : pacemakers</li> <li>- Biotronik : pacemakers</li> <li>- Microport : training pacemakers</li> </ul> |



## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry   |
|--------------------|--|
| Mairesse Georges H | <p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : antico</li> <li>- Medtronic : pacemakers</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Abbott : pacemakers</li> </ul>  |
| Margitfalvi Peter  | <p><b>2020</b></p> <p>Nothing to be declared</p>   |
| Marinskis Germanas | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Guidant Europe : AF ablation device clinical trial</li> </ul>  |
| Mascherbauer Julia | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : TAVI</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Biomedica : Coronary artery disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Pfizer : Cardiac amyloidosis</li> <li>- Edwards Lifesciences : Mitral valve repair</li> </ul> |
| Meine Mathias      | <p><b>2020</b></p> <p>Nothing to be declared</p>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                 | Type of Relationship with Industry   |
|------------------------|--|
| Milasinovic Goran      | <b>2020</b><br>Nothing to be declared  |
| Milliez Paul Ursmar    | <b>2020</b><br>Nothing to be declared  |
| Mjølstad Ole Christian | <b>2020</b><br>Nothing to be declared  |
| Mullens Wilfried       | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- Pfizer : consultancy</li> <li>- Astra Zeneca : speaker fees</li> <li>- Medtronic : speaker fees</li> <li>- Boehringer-Ingelheim : speakers fees</li> </ul> |
| Nagy Klaudia Vivien    | <b>2020</b><br>Nothing to be declared  |
| Papasavvas Ilias       | <b>2020</b><br>Nothing to be declared  |
| Poposka Lidija         | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- Alkaloid Skopje : CVD prevention</li> <li>- Bayer : NOAC</li> <li>- Pfizer : NOAC</li> </ul>   |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                        | Type of Relationship with Industry   |
|-------------------------------|--|
| Popov Sergey<br>Valentinovich | <b>2020</b><br><br>Nothing to be declared  |
| Prescott Eva                  | <b>2020</b><br><br>Nothing to be declared  |
| Raatikainen Pekka             | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- Abbott : Cardia rhythm management</li> <li>- Stereotaxis : Cardiac rhythm management</li> <li>- Biosense Webster : Cardiac rhythm management</li> <li>- Pfizer/BMS : Oral anticoagulation</li> </ul><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br><ul style="list-style-type: none"> <li>- Biosense Webster : Ventricular tachyarrhythmia ablation (unrestricted grant for international multicenter trial))</li> </ul> |
| Rakisheva Amina               | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillation</li> <li>- Novartis : Heart Failure</li> </ul>   |
| Reichlin Tobias               | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br><ul style="list-style-type: none"> <li>- Medtronic : Leadless Pacing &amp; extracardiac ICD</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Reichlin Tobias     | <p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Mapping System, Ablation Catheters, Pacemaker &amp; ICD's</li> <li>- Biotronik : Mapping System, Ablation Catheters, Pacemaker &amp; ICD's</li> <li>- Bayer : NOAC</li> <li>- Medtronic : Pacemaker &amp; ICD's</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Mapping &amp; Ablation</li> <li>- Abbott/SJM : PM &amp; ICD</li> <li>- Medtronic : PM &amp; ICD, Ablation</li> <li>- Boston Scientific : PM &amp; ICD, Mapping &amp; Ablation</li> <li>- Biotronik : PM, ICD &amp; ICM</li> </ul> |
| Ricci Renato Pietro | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- DOMPE' FARMACEUTICI S.P.A : ADVISORY BOARD</li> </ul>   |
| Rizov Mihail        | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Sammut Mark Adrian  | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Devices</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Sammur Mark Adrian | <b>2020</b><br>Travel and meeting support from healthcare industry, independent of the above activities.<br>- Biotronik : Devices and ablation  |
| Scherr Daniel      | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Boehringer-Ingelheim : Speaker fee<br>- Daiichi Sankyo : Speaker fee<br>- Medtronic : Speaker fee<br>- Pfizer : Speaker fee<br>- Biotronik : Speaker fee<br>- Bayer Healthcare : Speaker fee<br>- Zoll Medical : Speaker fee   |
| Sheahan Richard    | <b>2020</b><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Daiichi Sankyo : Honoria for presentations<br><br>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Daiichi Sankyo : Investigator<br><br>Travel and meeting support from healthcare industry, independent of the above activities.<br>- Servier : Travel support |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Shlyakhto Evgeny | <b>2020</b><br><br>Nothing to be declared   |
| Siliste Calin    | <b>2020</b><br><br>Nothing to be declared   |
| Sitges Marta     | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Abbott : Heart Valve Disease<br>- Edwards Lifesciences : Heart Valve Disease<br>- Medtronic : Heart Valve Disease<br><br>Travel and meeting support from healthcare industry, independent of the above activities.<br>- Abbott : Heart Valve Disease<br>- Edwards Lifesciences : Heart Valve Disease<br><br>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br>- Bristol Myers Squibb : Atrial Fibrillation<br>- Menarini : Continuous Education on Cardiovascular Diseases<br>- Novartis : Heart Failure<br>- Merck Sharp & Dohme : Hypercholesterolemia<br><br>Other Positions of Influence<br><br>Employment in healthcare industry (including part time) during the year for which you are declaring.<br>- Speaker and consultant for Abbot. |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Sousa Uva Miguel  | <b>2020</b><br><br>Nothing to be declared  |
| Sterlinski Maciej | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Abbott : CIEDs<br>- Medtronic : CIEDs<br>- Biotronik : CIEDs<br>- Pfizer : NOACs<br>- Zoll Medical : WCD  |
| Sutton Richard    | <b>2020</b><br><br>Financial Declaration<br><br>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Medtronic Inc. : Consultant - General<br>- Abbott Laboratories Consultant : Pacing, syncope and scientific writing<br><br>Other Positions of Influence<br><br>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.<br>- Healthcare - ALL AREAS OF CARDIOLOGY - Shareholder in Edwards Lifesciences Corp. and Boston Scientific Inc.<br><br>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.<br>- Member of the Medical Advisory Committee of Syncope Trust and Anoxic Reflex Syncope patients organisation |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                  | Type of Relationship with Industry   |
|-------------------------|--|
| Suwalski Piotr          | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiovascular surgery</li> <li>- St Jude Medical : cardiovascular surgery</li> <li>- Atricure : cardiovascular surgery</li> </ul>   |
| Svendsen Jesper Hastrup | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Advisory board</li> </ul> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- munksgaard (Danish publisher) : Editor of "Medicinsk Kompendium 19th edition"</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Medtronic : Research grant</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> <li>- Consultant for insurance company.</li> </ul> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Member of the Danish Heart Foundation</li> </ul> |



## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry  |
|-----------------------|---|
| Taborsky Milos        | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation therapy</li> <li>- Bayer Healthcare : Anticoagulation therapy</li> <li>- Astra Zeneca : CAD</li> <li>- Biotronik : Cardiac Pacing</li> </ul> |
| Touyz Rhian           | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Consultancy-expert opinion</li> </ul>   |
| Van Gelder Isabelle C | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial Fibrillation</li> <li>- Medtronic : Atrial Fibrillation</li> </ul>  |
| Velagic Vedran        | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : speaker fee</li> <li>- Novartis : speaker fee</li> <li>- Pfizer : speaker fee</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert             | Type of Relationship with Industry   |
|--------------------|--|
| Velagic Vedran     | <b>2020</b> <ul style="list-style-type: none"> <li>- Berlin Menarini : speaker fee</li> <li>- Krka Pharma : speaker fee</li> <li>- PLIVA : speaker fee</li> <li>- Servier : speaker fees</li> <li>- Medtronic : speaker fees, proctoring, investigator</li> </ul>  |
| Velchev Vasil      | <b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Pfizer : Eliquis</li> <li>- Actelion : PH</li> <li>- Boston Scientific : renal denervation</li> <li>- Bayer : xarelto</li> </ul>  |
| Veltmann Christian | <b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Cardiac Rhythm Management</li> <li>- Johnson &amp; Johnson : Catheter ablation</li> <li>- Cardiovascular Therapeutics : Heart Failure</li> <li>- Roche Diagnostics : Stroke prevention</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry  |
|-----------------------|---|
| Vernooy Kevin         | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : speaker fee</li> <li>- Philips : speaker fee</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : consultancy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Medtronic : investigator initiated research grant</li> </ul> |
| Vinther Michael       | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Voitk Jyri            | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Investigator</li> </ul>  |
| Vukmirovic Mihailo    | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Waltenberger Johannes | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : thrombosis</li> </ul>  |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry  |
|-----------------------|---|
| Waltenberger Johannes | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- German Heart Foundation (Deutsche Herzstiftung)</li> </ul>  |
| Whinnett Zachary      | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Cardiac pacing</li> <li>- Medtronic : Cardiac pacing</li> <li>- Micropace : Cardiac Pacing</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Medtronic : Cardiac Pacing</li> </ul>  |
| Witte Klaus           | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Medtronic : Heart failure</li> <li>- Abbott Vascular : Heart failure</li> <li>- Cardiac Dimensions : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Medtronic : Heart failure</li> </ul> |

## 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert          | Type of Relationship with Industry   |
|-----------------|--|
| Zarif John      | <b>2020</b><br><br>Nothing to be declared  |
| Zecchin Massimo | <b>2020</b><br><br>Financial Declaration<br><br>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br>- Bristol Myers Squibb : PI in the ARTESIA study |
| Zupan Igor      | <b>2020</b><br><br>Nothing to be declared  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Abdelhamid Magdy | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>  |
| Aboyans Victor   | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Bristol Myers Squibb : Antithrombotic therapies</li> <li>- Astrazeneca : Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Peripheral Artery Disease</li> </ul> |
| Antoniou Sotiris | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees for education - AF</li> <li>- Bayer AG : speaker fees for education - AF</li> <li>- Daiichi Sankyo : speaker fees for education -AF</li> <li>- Astra Zeneca : speaker fees for education - CVD</li> </ul>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Antoniou Sotiris    | <p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br/>- Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.<br/>- Member of Arrhythmia alliance medical advisory panel</p> |
| Arbelo Elena        | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Biosense Webster : Atrial fibrillation</p>   |
| Asteggiano Riccardo | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.<br/>- Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</p>   |
| Baigent Colin       | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).<br/>- Boehringer-Ingelheim : Cardiovascular and renal disease</p>  |
| Baumbach Andreas    | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Astra Zeneca : Pharmacology</p>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert            | Type of Relationship with Industry   |
|-------------------|--|
| Baumbach Andreas  | <p><b>2020</b></p> <ul style="list-style-type: none"> <li>- CERC : Research Organisation: Events Committees</li> <li>- Abbot Vascular : Stents</li> <li>- Microport : Stents</li> <li>- Sinomed : Stents</li> <li>- Venus Medtech : Valves, CEP</li> </ul>   |
| Borger Michael A  | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul>   |
| Celutkienė Jelena | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Amgen : heart failure</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : heart failure</li> </ul> |



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Cikes Maja           | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation, amyloidosis</li> <li>- Astra Zeneca : coronary heart disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Orion : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure</li> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul> |
| Collet Jean-Philippe | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Astra Zeneca : Post-PCI antiplatelet treatment</li> </ul>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Collet Jean-Philippe | <p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul>  |
| Falk Volkmar         | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> </ul> |
| Fauchier Laurent     | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- XO : Healthcare</li> </ul>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                 | Type of Relationship with Industry  |
|------------------------|---|
| Gale Christopher Peter | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acs hf</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : af</li> <li>- Abbott : diabetes</li> </ul>  |
| Halvorsen Sigrun       | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Sanofi Aventis : Lipidlowering</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart failure</li> </ul> |
| Iung Bernard           | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Jaarsma Tiny           | <p><b>2020</b></p> <p>Nothing to be declared</p>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                | Type of Relationship with Industry   |
|-----------------------|--|
| Konradi Aleksandra    | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertension</li> </ul>  |
| Koskinas Konstantinos | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul> |
| Kotecha Dipak         | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> </ul>  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert         | Type of Relationship with Industry  |
|----------------|---|
| Kotecha Dipak  | <p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul> |
| Landmesser Ulf | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory Board fee</li> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Bayer AG : Research Grant</li> </ul>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Lewis Basil S    | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Vifor International : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul> |
| Linhart Ales     | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> </ul>   |
| Lochen Maja-Lisa | <p><b>2020</b></p> <p>Nothing to be declared</p>  |
| Neubeck Lis      | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial fibrillation</li> </ul>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert                  | Type of Relationship with Industry  |
|-------------------------|---|
| Neubeck Lis             | <b>2020</b> <ul style="list-style-type: none"> <li>- Pfizer : Atrial fibrillation</li> <li>- Novo-Nordisk : CVD diabetes</li> <li>- Servier : Digital health</li> </ul>   |
| Nielsen Jens Cosedis    | <b>2020</b> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Member of Danish Heart Foundation</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- I received institutional research grants from the Novo Nordisk Foundation</li> </ul>  |
| Petersen Steffen Erhard | <b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</li> </ul> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</li> </ul> |
| Prescott Eva            | <b>2020</b> <p>Nothing to be declared</p>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert          | Type of Relationship with Industry   |
|-----------------|--|
| Rakisheva Amina | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillation</li> <li>- Novartis : Heart Failure</li> </ul>   |
| Sitges Marta    | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continuous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul> |



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

| Expert       | Type of Relationship with Industry  |
|--------------|---|
| Sitges Marta | <p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.<br/>- Speaker and consultant for Abbot.</p>  |
| Touyz Rhian  | <p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.<br/>- Novartis : Consultancy-expert opinion</p> |